β受体阻滞剂与腹主动脉瘤腔内修复术后死亡率增加相关但未减少再干预
基于血管质量倡议(VQI)2003–2021年注册数据,50,411例接受EVAR的患者按出院时是否使用β受体阻滞剂(BB)分组,比较30天和1年死亡与再干预。BB组30天死亡0.33% vs 无BB组0.20%(P=0.007),1年死亡3.19% vs 2.35%(P<0.001),Cox模型1年死亡风险比为1.26(1.10–1.41,P<0.001)。总体再干预无显著差异(P=0.061),1年移植物闭塞再干预BB组11.77% vs 无BB组18.70%(P=0.002)。
要点
- EVAR术后使用BB与30天和1年死亡率升高相关,校正后1年死亡HR为1.26(1.10–1.41)。
- BB组与无BB组总体再干预率无显著差异(P=0.061)。
- 1年移植物闭塞再干预BB组11.77% vs 无BB组18.70%(P=0.002),其余原因再干预无显著差异。
核心结论
- 尽管BB对动脉瘤行为有理论益处,但最大全国血管手术数据库显示EVAR术后使用BB的患者再干预发生率未降低,且死亡率更高。
研究设计与样本
- 基于血管质量倡议(VQI)2003–2021年注册数据的分析,纳入接受EVAR并在出院时按是否使用BB分层的患者,于30天和1年随访评估。
主要发现
- 共50,411例患者,BB组28,866例(57.3%),无BB组21,545例(42.7%)。
- BB组与无BB组总体再干预无显著差异(P=0.061)。
- 30天随访时,两组任何原因再干预均无显著差异。
- 1年随访时,BB组因移植物闭塞需再干预的比例低于无BB组(BB组11.77% vs 无BB组18.70%,P=0.002),其余原因再干预无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Predictors of sac behavior after endovascular aortic aneurysm repair (EVAR) and the impact of sac behavior on long-term survival are not well known. There are limited multicenter trials studying the impact of beta blockers (BBs) on sac behavior. BBs have consistently failed to show a benefit on abdominal aortic aneurysm sac regression in patients with connective tissue disorders and the general population. This study aims to assess the association between BBs and sac behavior after EVAR. METHODS: Patients undergoing EVAR registered in Vascular Quality Initiative (2003-2021) stratified by BB and no BB on discharged after an index procedure were assessed at follow-up of 30 days and 1 year. The primary outcomes included mortality and reintervention at 30 days and 1 year. The causes of reintervention were also studied at the defined time endpoints. Categorical and continuous variables were analyzed separately for association between the 2 groups. A P value of <0.05 was considered statistically significant. RESULTS: A total of 50,411 patients, stratified by BB (28,866; 57.3%), and no BB (21,545; 42.7%) were studied. Patients with hypertension, diabetes, chronic obstructive pulmonary disease, coronary artery disease, prior history of coronary artery bypass graft or percutaneous coronary intervention, prior angioplasty or stent, lower extremity bypass, carotid surgery, major amputation, and smokers were more likely to be on a BB at the time of discharge (P < 0.05). There was no significant difference in reinterventions when comparing patients with and without BB (P = 0.061). At 30-day follow-up, there was no significant difference between the 2 groups for any cause of reintervention. At 1-year follow-up, patients on BB were less likely to need reintervention for graft occlusion (no BB 18.70%, BB 11.77%, P = 0.002). There was no significant difference in reintervention for all other causes at 1-year follow-up. There was an increase in 30-day (no BB 0.20%, BB 0.33%, P = 0.007) and 1-year mortality (no BB 2.35%, BB 3.19%, P < 0.001) in patients on BBs. A time to event adjusted analysis based on Cox proportional hazard model revealed a 26% higher risk of 1-year mortality for patients on BB (hazard ratio: 1.26 [1.10-1.41] P < 0.001). CONCLUSIONS: Despite theoretical benefits of BBs on aneurysm behavior, review of the largest national vascular surgery database shows that patients on BBs do not have lower incidence of endovascular reinterventions after EVAR while additionally showing a higher mortality in this patient population.
引用
- Vicario-Feliciano R, Zil-E-Ali A, Aziz F, et al. Beta Blockers are Associated with Increased Mortality Without a Decrease in Reinterventions After Endovascular Abdominal Aortic Repair (EVAR). Ann Vasc Surg. 2024. PMID: 39103012. doi:10.1016/j.avsg.2024.07.104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。